&nbsp;

Dec 1969

Drug

riTUXimab

Other Name(s): Rituxan® , Truxima™ , Riximyo™ , Ruxience™ , Riabni™

Quick Link(s):

Oct 2023

Drug

bendamustine

Other Name(s): Treanda®

Quick Link(s):

Nov 2024

Drug

brentuximab vedotin

Other Name(s): Adcetris®

Quick Link(s):

Sep 2024

Drug

romidepsin

Other Name(s): Istodax®

Quick Link(s):

Mar 2023

Drug

ramucirumab

Other Name(s): Cyramza®

Quick Link(s):

Mar 2023

Drug

blinatumomab

Other Name(s): Blincyto®

Quick Link(s):

Oct 2024

Regimen

BMP

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - Previously Untreated - Multiple Myeloma

ODB - General Benefit

melphalan - oral tablets

ODB - General Benefit

prednisone

Drugs Used:

Quick Link(s):

Regimen Monograph

Regimen

BORT

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - Relapsed or Refractory Multiple Myeloma

ODB - General Benefit

dexamethasone

Drugs Used:

bortezomib,

dexamethasone

Quick Link(s):

Regimen Monograph

Nov 2024

Regimen

RITU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) - Single Agent - Indolent Lymphoma

Drugs Used:

riTUXimab

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

RITU(MNT)

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma

Drugs Used:

riTUXimab

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

BEND

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

New Drug Funding Program

Bendamustine - First Line - Chronic Lymphocytic Leukemia

Drugs Used:

bendamustine